Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by SouthernTierTomon Sep 18, 2020 8:23am
227 Views
Post# 31579911

Great job for shareholders buy "Cal et al"

Great job for shareholders buy "Cal et al"

This is HUUUUGE ... multiple phase 2's??


This is now worth close to 2B CAD or about 18 times that of EDTXF..

AND..being S O L D to the public...I love you Canada..I love Canadien Bio

PAY ATTENTION to the depressed stuff insiders like to BUY on the cheap!

Trillium Therapeutics closes offering for $149M (U.S.)

 

2020-09-16 16:16 ET - News Release

 

Dr. Jan Skvarka reports

TRILLIUM CLOSES US$150 MILLION PUBLIC OFFERING OF COMMON SHARES

Trillium Therapeutics Inc. has closed its previously announced underwritten public offering of common shares of the company at a public offering price of $13 (U.S.) per common share. It sold 11.5 million common shares in the offering, including the full exercise by the underwriters of their option to purchase up to an additional 1.5 million common shares.

The gross proceeds from the offering were $149.5-million (U.S.), before deducting underwriting commissions and other offering expenses. The company intends to use the net proceeds of the offering for its continuing and planned clinical trials for its CD47 program, including drug supply, and for working capital and general corporate purposes.

"We would like to thank all investors who placed their trust in both our unique CD47 assets as well as Trillium people. We are committed to speedily advance our investigational program into multiple phase 2 trials, and further drive evolution of the oncology treatment paradigm toward greater adoption of novel, groundbreaking immunotherapies," said Dr. Jan Skvarka, Trillium's president and chief executive officer

<< Previous
Bullboard Posts
Next >>